Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan

Abstract “Real-world” data on the nationwide epidemiology and treatment patterns of multiple sclerosis (MS) is very scarce in Asia. This study is aim to evaluate the 10-years trends in epidemiology and treatment patterns of MS with Taiwan’s National Health Insurance Database (NHIRD). Patients aged 2...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chia-Yun Hsu, Long-Sun Ro, Li-Ju Chen, Chun-Wei Chang, Kuo-Hsuan Chang, I-Hsuan Wu, Amy Lin, Fei-Yuan Hsiao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/61b4b716135548868983d806aa784291
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61b4b716135548868983d806aa784291
record_format	dspace
spelling	oai:doaj.org-article:61b4b716135548868983d806aa7842912021-12-02T14:22:43ZEpidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan10.1038/s41598-021-86347-32045-2322https://doaj.org/article/61b4b716135548868983d806aa7842912021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86347-3https://doaj.org/toc/2045-2322Abstract “Real-world” data on the nationwide epidemiology and treatment patterns of multiple sclerosis (MS) is very scarce in Asia. This study is aim to evaluate the 10-years trends in epidemiology and treatment patterns of MS with Taiwan’s National Health Insurance Database (NHIRD). Patients aged 20 years or older and were newly diagnosed with MS between 2007 and 2016 were identified. The crude incidences of MS were presented annually and stratified by sex and age. Baseline characteristics and treatment patterns, particularly disease-modifying drugs (DMDs), were also analyzed. This study included 555 MS patients (mean age was 36.9 and 74.4% were female). The crude incidence rate of MS decreased slightly from 0.43 per 100,000 persons in 2007 to 0.24 per 100,000 persons in 2015. The female to male ratios remained mainly between 2 to 3. Approximately 80% of MS patients received initial DMDs, with interferon β-1a as the dominant one. Furthermore, 37.5% of MS patients received subsequent DMDs, with fingolimod being the most frequently used. The median times from diagnosis to initial and to subsequent DMDs were 77 and 1239 days, respectively. This nationwide study provides up-to-date and sophisticated estimates of MS epidemiology and treatment pattern in “real-world” setting in Taiwan.Chia-Yun HsuLong-Sun RoLi-Ju ChenChun-Wei ChangKuo-Hsuan ChangI-Hsuan WuAmy LinFei-Yuan HsiaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chia-Yun Hsu Long-Sun Ro Li-Ju Chen Chun-Wei Chang Kuo-Hsuan Chang I-Hsuan Wu Amy Lin Fei-Yuan Hsiao Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
description	Abstract “Real-world” data on the nationwide epidemiology and treatment patterns of multiple sclerosis (MS) is very scarce in Asia. This study is aim to evaluate the 10-years trends in epidemiology and treatment patterns of MS with Taiwan’s National Health Insurance Database (NHIRD). Patients aged 20 years or older and were newly diagnosed with MS between 2007 and 2016 were identified. The crude incidences of MS were presented annually and stratified by sex and age. Baseline characteristics and treatment patterns, particularly disease-modifying drugs (DMDs), were also analyzed. This study included 555 MS patients (mean age was 36.9 and 74.4% were female). The crude incidence rate of MS decreased slightly from 0.43 per 100,000 persons in 2007 to 0.24 per 100,000 persons in 2015. The female to male ratios remained mainly between 2 to 3. Approximately 80% of MS patients received initial DMDs, with interferon β-1a as the dominant one. Furthermore, 37.5% of MS patients received subsequent DMDs, with fingolimod being the most frequently used. The median times from diagnosis to initial and to subsequent DMDs were 77 and 1239 days, respectively. This nationwide study provides up-to-date and sophisticated estimates of MS epidemiology and treatment pattern in “real-world” setting in Taiwan.
format	article
author	Chia-Yun Hsu Long-Sun Ro Li-Ju Chen Chun-Wei Chang Kuo-Hsuan Chang I-Hsuan Wu Amy Lin Fei-Yuan Hsiao
author_facet	Chia-Yun Hsu Long-Sun Ro Li-Ju Chen Chun-Wei Chang Kuo-Hsuan Chang I-Hsuan Wu Amy Lin Fei-Yuan Hsiao
author_sort	Chia-Yun Hsu
title	Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
title_short	Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
title_full	Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
title_fullStr	Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
title_full_unstemmed	Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
title_sort	epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in taiwan
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/61b4b716135548868983d806aa784291
work_keys_str_mv	AT chiayunhsu epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT longsunro epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT lijuchen epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT chunweichang epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT kuohsuanchang epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT ihsuanwu epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT amylin epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan AT feiyuanhsiao epidemiologytreatmentpatternsandhealthcareutilizationsinmultiplesclerosisintaiwan
_version_	1718391489966374912

Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan

Ejemplares similares